These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 22739140)

  • 1. Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy?
    Budha NR; Frymoyer A; Smelick GS; Jin JY; Yago MR; Dresser MJ; Holden SN; Benet LZ; Ware JA
    Clin Pharmacol Ther; 2012 Aug; 92(2):203-13. PubMed ID: 22739140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development.
    Smelick GS; Heffron TP; Chu L; Dean B; West DA; Duvall SL; Lum BL; Budha N; Holden SN; Benet LZ; Frymoyer A; Dresser MJ; Ware JA
    Mol Pharm; 2013 Nov; 10(11):4055-62. PubMed ID: 24044612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medical therapy for gastroesophageal reflux disease in 2007.
    Katz PO
    Rev Gastroenterol Disord; 2007; 7(4):193-203. PubMed ID: 18192955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antisecretory potential of pantoprasole (sanpraz)].
    Kurilovich SA; Chernosheĭkina LE
    Eksp Klin Gastroenterol; 2008; (7):119-22. PubMed ID: 19334455
    [No Abstract]   [Full Text] [Related]  

  • 5. Control of intragastric pH and its relationship to gastroesophageal reflux disease outcomes.
    Katz PO; Johnson DA
    J Clin Gastroenterol; 2011 Oct; 45(9):748-54. PubMed ID: 21694609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of proton-pump inhibitor-refractory non-erosive reflux disease according to multichannel intraluminal impedance-pH monitoring.
    Kohata Y; Fujiwara Y; Machida H; Okazaki H; Yamagami H; Tanigawa T; Watanabe K; Watanabe T; Tominaga K; Arakawa T
    J Gastroenterol Hepatol; 2012 Apr; 27 Suppl 3():58-62. PubMed ID: 22486873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring.
    Mainie I; Tutuian R; Shay S; Vela M; Zhang X; Sifrim D; Castell DO
    Gut; 2006 Oct; 55(10):1398-402. PubMed ID: 16556669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nocturnal gastric acid breakthrough is not associated with night-time gastroesophageal reflux in GERD patients.
    Weigt J; Kandulski A; Büsch F; Malfertheiner P
    Dig Dis; 2009; 27(1):68-73. PubMed ID: 19439964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug interactions produced by proton pump inhibitors: not simply a pH effect.
    Mullin JM; Schrogie JJ
    Clin Pharmacol Ther; 2013 Feb; 93(2):150. PubMed ID: 23169430
    [No Abstract]   [Full Text] [Related]  

  • 10. [Night acid "bursting": treatment of patients with gastroesophageal reflux disease].
    Vasil'ev IuV; Beliaeva VS
    Eksp Klin Gastroenterol; 2007; (3):83-91. PubMed ID: 17937011
    [No Abstract]   [Full Text] [Related]  

  • 11. Response to "Drug interactions produced by proton pump inhibitors: not simply a pH effect".
    Budha NR; Benet LZ; Ware JA
    Clin Pharmacol Ther; 2013 Feb; 93(2):151. PubMed ID: 23169432
    [No Abstract]   [Full Text] [Related]  

  • 12. Weakly acidic refluxes have a major role in the pathogenesis of proton pump inhibitor-resistant reflux oesophagitis.
    Frazzoni M; Conigliaro R; Melotti G
    Aliment Pharmacol Ther; 2011 Mar; 33(5):601-6. PubMed ID: 21198705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review article: physiologic and clinical effects of proton pump inhibitors on non-acidic and acidic gastro-oesophageal reflux.
    Miner PB
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():25-32. PubMed ID: 16483267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitors in GORD An overview of their pharmacology, efficacy and safety.
    Savarino V; Di Mario F; Scarpignato C
    Pharmacol Res; 2009 Mar; 59(3):135-53. PubMed ID: 18977444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of esophageal and intragastric pH with compounded and manufactured omeprazole in patients with reflux esophagitis: a pilot study.
    Moretzsohn LD; Carvalho EB; Franco JD; Soares MP; Brito EM; Belarmino K; Coelho LG
    Can J Clin Pharmacol; 2009; 16(1):e264-72. PubMed ID: 19383986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
    Howden CW; Ballard ED; Koch FK; Gautille TC; Bagin RG
    J Clin Gastroenterol; 2009 Apr; 43(4):323-6. PubMed ID: 18758373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proton pump inhibitors reduce the size and acidity of the acid pocket in the stomach.
    Rohof WO; Bennink RJ; Boeckxstaens GE
    Clin Gastroenterol Hepatol; 2014 Jul; 12(7):1101-1107.e1. PubMed ID: 24726906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twenty-four-hour esophageal impedance-pH monitoring in healthy preterm neonates: rate and characteristics of acid, weakly acidic, and weakly alkaline gastroesophageal reflux.
    López-Alonso M; Moya MJ; Cabo JA; Ribas J; del Carmen Macías M; Silny J; Sifrim D
    Pediatrics; 2006 Aug; 118(2):e299-308. PubMed ID: 16831894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux.
    Omari TI; Haslam RR; Lundborg P; Davidson GP
    J Pediatr Gastroenterol Nutr; 2007 Jan; 44(1):41-4. PubMed ID: 17204951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapy resistance of gastro-oesophageal reflux symptoms: acid reflux, non-acid reflux or no reflux].
    Bredenoord AJ; Smout AJ
    Ned Tijdschr Geneeskd; 2008 Nov; 152(47):2548-52. PubMed ID: 19174935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.